Medical Developments International (ASX:MVP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Medical Developments International (ASX:MVP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4C and Quarterly Activity Report -30 September 2026
CEO Transition
Medical Developments International appoints CFO Anita James as interim CEO as Brent MacGregor steps down
Corporate Governance Statement 2026
Notice of Annual General Meeting 2026
Annual Report 2026
Medical Developments International reports stronger FY26 earnings and Penthrox growth
Appendix 4G 2026
Notification of cessation of securities - MVP
Date of AGM and Closing Date for Director Nominations
MVP Announces FY26 Full Year Results
Medical Developments International posts FY26 profit growth with strong Penthrox volume gains and paediatric label approval
FY26 Full year Results Investor Presentation
MVP delivers solid FY26 results with Penthrox® volume growth and expanded paediatric market in Europe
FY26 Full Year Results
Medical Developments International reports 9% revenue growth and 566% profit increase for FY26, driven by Pain Management segment
Change in substantial holding
FY26 Full Year Results Announcement Details
Medical Developments International to announce FY26 results on 20 August 2026